A new survival breakthrough in pancreatic cancer: what daraxonrasib means for patients

Pancreatic cancer has long been one of the most difficult cancers I treat. Most patients are diagnosed after the disease has already spread, and for decades our chemotherapy options — while sometimes helpful — rarely changed the overall trajectory of the disease. This summer, that picture began to shift in a meaningful way, and I want to walk my patients and their families through what happened, because the excitement in the oncology community over the past few weeks is real and, for once, well earned.

The news centers on a drug called daraxonrasib, and results from a pivotal phase 3 trial called RASolute 302, published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting. To understand why this matters, it helps to know a bit about the biology. More than 90% of pancreatic ductal adenocarcinomas (the most common type of pancreatic cancer) are driven by mutations in a gene called KRAS. For thirty years, KRAS was considered "undruggable" — its shape made it almost impossible for medications to bind to and switch off. Daraxonrasib belongs to a new class of drugs called RAS(ON) inhibitors, designed to lock onto the active form of RAS proteins — including several of the specific KRAS mutations most common in pancreatic cancer — and shut down the signal that drives tumor growth.

RASolute 302 enrolled about 500 patients with metastatic pancreatic cancer whose disease had already progressed after one prior line of chemotherapy — exactly the group of patients where our options have traditionally been weakest. Patients were randomized to receive daraxonrasib or standard second-line chemotherapy. The results were striking. Median overall survival nearly doubled, from 6.6–6.7 months with chemotherapy to 13.2 months with daraxonrasib. Progression-free survival — the time before the cancer started growing again — also roughly doubled, from about 3.5 months to 7.2–7.3 months. The objective response rate, meaning the tumor visibly shrank, was 31.6–33.2% with daraxonrasib compared with 11.2–11.8% with chemotherapy.

What struck many oncologists, myself included, is that daraxonrasib worked not only in tumors carrying the classic KRAS mutations but also, to a meaningful degree, in RAS "wild-type" tumors — patients who previously had no targeted option at all. This broadens the potential population who could benefit well beyond what earlier RAS-targeted drugs achieved.

Equally important for a disease notorious for hard-to-tolerate treatment: daraxonrasib was better tolerated than chemotherapy in this trial. Grade 3 or higher side effects occurred in 43.6% of patients on daraxonrasib versus 57.5% on chemotherapy, and only 1.2% of patients stopped treatment due to side effects, compared with 11.2% on chemotherapy. That combination — better efficacy and better tolerability — is unusual and is part of why this result is being described as practice-changing rather than incremental.

I want to be careful not to overstate where we are. This trial was conducted in patients who had already received one round of chemotherapy, so daraxonrasib is not yet established as a first-line therapy, and it is not a cure — median survival of 13.2 months, while nearly double the old standard, still reflects a serious disease. Longer-term follow-up, quality-of-life data, and studies combining daraxonrasib with chemotherapy in earlier lines of treatment are already underway and will help define exactly how this drug should be used going forward. Regulatory review is expected to follow given the strength of this data.

For patients and families facing a pancreatic cancer diagnosis today, my honest advice is this: ask your oncologist specifically about RAS(ON) inhibitor trials and about daraxonrasib eligibility, particularly if your disease has progressed after first-line chemotherapy. Molecular testing of the tumor (to identify the specific KRAS status) is more relevant now than ever, since it may open the door to this and other targeted therapies. Pancreatic cancer remains one of our hardest fights, but for the first time in a long time, the data genuinely support hope for a meaningfully longer, better-tolerated course of treatment.

Source: Daraxonrasib in the RASolute 302 phase 3 trial, New England Journal of Medicine, 2026; presented at the ASCO 2026 Annual Meeting.